Stockscreener 앱 받기
7.56
2.45%
-0.19
시장 영업 전:
7.56
전일 마감가:
$7.75
열려 있는:
$7.69
하루 거래량:
144.38K
Relative Volume:
1.35
시가총액:
$94.94M
수익:
$4.28M
순이익/손실:
$-7.28M
주가수익비율:
-9.2806
EPS:
-0.8146
순현금흐름:
$-6.17M
1주 성능:
-0.66%
1개월 성능:
+25.17%
6개월 성능:
+0.67%
1년 성능:
+174.91%
1일 변동 폭
$7.56
$7.99
1주일 범위
$6.94
$7.99
52주 변동 폭
$2.21
$9.33
Neuraxis Inc Stock (NRXS) Company Profile
명칭
Neuraxis Inc
전화
(812) 689-0791
주소
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
7.56 | 94.94M | 4.28M | -7.28M | -6.17M | -0.8146 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuraxis Inc 주식(NRXS)의 최신 뉴스
Craig-Hallum Maintains Neuraxis(NRXS.US) With Buy Rating, Maintains Target Price $13 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com
NeurAxis secures major insurer coverage for IB-Stim device - Investing.com
NeurAxis secures major insurer coverage for IB-Stim device By Investing.com - Investing.com India
NeurAxis Announces Medical Coverage Policy Milestone, - GlobeNewswire
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives - Yahoo Finance
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference - Yahoo Finance
Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock? - TradingView
NeurAxis at iAccess Alpha conference: payer wins drive growth By Investing.com - Investing.com Nigeria
NRXS: Strong insurance coverage and clinical data position the company for rapid growth through 2027 - tradingview.com
NeurAxis at iAccess Alpha conference: payer wins drive growth - Investing.com
Is Kodak having a "Kodak moment?" 2 watchlist stocks. - TradingView
NRXS Forecast & Price Target - TradingKey
Neuraxis Inc. (NRXS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Neuraxis Inc. (NRXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Neuraxis | 4: Statement of changes in beneficial ownership of securities-Officer Carrico Thomas Joeseph - Moomoo
Neuraxis (NRXS) Q2 2026 Earnings: EPS Beats Its Estimate in the Latest Session; Price Move: Shares Finish 1.91% Down in the Current UpdateEarnings Expansion Phase - vinanet.vn
NeurAxis Earnings Call Signals High Growth, High Hurdles - TipRanks
NeurAxis Enhances Executive and Director Equity Compensation - TipRanks
Neuraxis (NRXS) grants CEO 199K instantly vesting stock units - Stock Titan
NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up - NewsBreak: Local News & Alerts
Neuraxis (NRXS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Jumps 32%Performance Review - vinanet.vn
NRXS Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 32% Stock SurgeEarnings Per Share - vinanet.vn
Neuraxis Inc. (NRXS) Q2 2026 Earnings: Narrower Loss Beats Expectations as Stock Holds SteadyStrong Earnings Momentum - vinanet.vn
NRXS Q2 2026 Earnings: 41.79% EPS Beat Signals Cost Discipline, Yet Shares Slip 1.26%Return On Assets - vinanet.vn
NeurAxis revenues up 116% to USD 1.9M in Q2 2026 - Medical Buyer
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
NeurAxis (NRXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Could NeurAxis (NASDAQ:NRXS) Reshape Nasdaq Composite Focus? - Kalkine Media
Transcript : NeurAxis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
NeurAxis (NASDAQ:NRXS): What Could Today’s Update Reveal About Pediatric Therapy Adoption And Reimbursement? - Kalkine Media
NRXS: Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth - TradingView
Earnings call transcript: NeurAxis falls on Q2 2026 EPS miss despite 116% revenue growth - Investing.com
NeurAxis reports 116% revenue growth in second quarter 2026 By Investing.com - Investing.com Nigeria
NeurAxis reports 116% revenue growth in second quarter 2026 - Investing.com
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth - The Manila Times
NRXS: Q2 2026 revenue surged 116% year-over-year, with gross margin up to 85.9% and strong cash position - TradingView
NRXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NeurAxis (NYSE American: NRXS) doubles sales yet warns on going concern - Stock Titan
Earnings To Watch: Neuraxis Inc (NRXS) Q2 2026 -- GF Value Sees 55% Downside - Yahoo Finance
NeurAxis, Inc. (NRXS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
NeurAxis宣佈爲IB-Stim PENFS療法增加美國中大西洋地區的覆蓋範圍，將服務擴展至超過500,000人 - Moomoo
Neuraxis Expands Payer Coverage for Percutaneous Electrical Nerve Field Stimulation and Ib-Stim Treatment - marketscreener.com
NeurAxis Expands Payer Coverage with New Policies - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Neuraxis Q1 2026 Earnings: Narrower-Than-Expected Loss as EPS Beats Consensus by 7.12%Guidance Revision Trend - dars.gov.et
NRXS|Neuraxis Inc|Price:6.735|Chg%:+0.485 - TradingKey
Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRXS Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineCFO Commentary Report - dars.gov.et
Neuraxis Inc (NRXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):